Page last updated: 2024-11-12

mepitiostane

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

mepitiostane: orally active anti-estrogenic steroid; RN refers to (2alpha,3alpha,5alpha,17beta)-isomer; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9909202
CHEMBL ID2104860
CHEBI ID31818
SCHEMBL ID13123
MeSH IDM0048599

Synonyms (37)

Synonym
5-alpha-androstane, 2-alpha,3-alpha-epithio-17-beta-(1-methoxycyclopentyloxy)-
mepitiostano [inn-spanish]
mepitiostane [inn:jan]
ccris 2779
mepitiostane
10364s
cyclopentanone, 2-alpha, 3-alpha-epithio-5-alpha-androstan-17-beta-yl methyl acetal
androstane, 2,3-epithio-17-((1-methoxycyclopentyl)oxy)-, (2-alpha,3-alpha,5-alpha,17-beta)
androstane, 2,3-epithio-17-((1-methoxycyclopentyl)oxy)-, (2alpha,3alpha,5alpha,17beta)-
s 10364
2-alpha,3-alpha-epithio-17-beta-yl 1-methoxycyclopentyl ether
cyclopentanone 2alpha,3alpha-epithio-5alpha-androstan-17beta-yl methyl acetal
mepitiostanum [inn-latin]
D01602
mepitiostane (jp17/inn)
thioderon (tn)
21362-69-6
mepitiostano
unii-o00404969k
mepitiostanum
o00404969k ,
AKOS015904663
thioderon
CHEMBL2104860
SCHEMBL13123
mepitiostane [mi]
mepitiostane [mart.]
mepitiostane [who-dd]
mepitiostane [jan]
mepitiostane [inn]
cyclopentanone 2.alpha.,3.alpha.-epithio-5.alpha.-androstan-17.beta.-yl methyl acetal
CHEBI:31818
Q6817819
DTXSID001016882
(1s,3as,3br,5as,6as,7ar,8as,8bs,10as)-1-((1-methoxycyclopentyl)oxy)-8a,10a-dimethylhexadecahydro-1h-cyclopenta[7,8]phenanthro[2,3-b]thiirene
(1s,2s,4r,6s,8s,11r,12s,15s,16s)-15-(1-methoxycyclopentyl)oxy-2,16-dimethyl-5-thiapentacyclo[9.7.0.02,8.04,6.012,16]octadecane
NCGC00522025-01

Research Excerpts

Treatment

Treatment with mepitiostane was started and 1 month later obvious elevation of hemoglobin concentration, white cell and platelet count was observed.

ExcerptReferenceRelevance
"When treatment with mepitiostane was combined with ACE inhibitor, anemia was significantly improved but without evidence of changes in circulating Epo concentrations or indices of renin-angiotensin activity."( Worsening of anemia by angiotensin converting enzyme inhibitors and its prevention by antiestrogenic steroid in chronic hemodialysis patients.
Fujishima, M; Motomura, K; Onoyama, K; Sanai, T, 1989
)
0.59
"Treatment with mepitiostane was started and 1 month later obvious elevation of hemoglobin concentration, white cell and platelet count was observed."( [Complete remission by mepitiostane in hypoplastic leukemia].
Ichiba, S; Imura, H; Ito, M; Nakabou, Y; Nakamura, K; Okuno, Y; Sugiyama, H; Suzuki, S; Takahashi, T, 1989
)
0.93
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
organic molecular entityAny molecular entity that contains carbon.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Research

Studies (36)

TimeframeStudies, This Drug (%)All Drugs %
pre-199022 (61.11)18.7374
1990's10 (27.78)18.2507
2000's2 (5.56)29.6817
2010's2 (5.56)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 20.06

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index20.06 (24.57)
Research Supply Index3.76 (2.92)
Research Growth Index4.52 (4.65)
Search Engine Demand Index18.60 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (20.06)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials6 (16.67%)5.53%
Reviews1 (2.78%)6.00%
Case Studies8 (22.22%)4.05%
Observational0 (0.00%)0.25%
Other21 (58.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]